The Pennovation Center published a Product Spotlight highlighting our recently launched oYo-Link™ Oligo Custom product. This powerful new bio-conjugation product allows researchers to site-specifically label their antibodies with synthetic strands of DNA, enabling applications such as iPCR, Proximity Ligation Assays, and more.
oYo-Link Oligo enables precise attachment of either single-stranded or double-stranded DNA with user-defined sequences to the researchers’ antibody of choice. This is enabled by AlphaThera’s proprietary oYo-Link conjugation technology stemming from the publication titled “LASIC: Light Activated Site-Specific Conjugation of Native IgGs”. The DNA can be over 80 bases in length and are user-defined. The oYo-Link site-specific bioconjugation method ensures that the customer’s oligonucleotide attaches precisely to the Fc-constant region of their antibody, guaranteeing well-defined antibody-oligonucleotide conjugate ratios and improved antibody binding performance.
Applications of this product are continuing to garner enthusiasm in the research community. Antibody-oligo conjugates combine the specificity of antibodies with the amplification power of DNA sequencing to truly offer a next-generation assay tool. The antibodies bind specific target cell populations or subcellular features, and the attached oligonucleotide offers a method of identification and quantification of this bound target. Some of the applications of oYo-Link Oligo include advanced multiplexing, ultrasensitive Immuno-PCR, and Proximity Ligation Assays
